Lack of sufficient tissue for molecular diagnosis [90], tumor heterogeneity [91], different failure rates of tumor genotyping methods used in routine clinical settings for the detection of EGFR, ALK, and KRAS [30], and associated risks and costs are some of the limitations that make liquid biopsy an appealing future surrogate of tissue biopsy in lung cancer management. Here, ALK is linked to lung cancer.